Adage Capital Partners Gp, L.L.C. Aerie Pharmaceuticals Inc Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $6.91 Million - $9.79 Million	-390,100 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$18.41 - $28.0 $24.1 Million - $36.7 Million	-1,310,000 Reduced 77.05%	390,100 $7.5 Million
Q2 2019 Aug 14, 2019	SELL	$28.97 - $48.21 $16.1 Million - $26.8 Million	-555,900 Reduced 24.64%	1,700,100 $50.2 Million
Q1 2019 May 15, 2019	SELL	$36.32 - $49.25 $32.3 Million - $43.9 Million	-890,411 Reduced 28.3%	2,256,000 $107 Million
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $16.4 Million - $29.8 Million	496,411 Added 18.73%	3,146,411 $114 Million
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $8.42 Million - $11.1 Million	-150,000 Reduced 5.36%	2,650,000 $163 Million
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $13 Million - $19.1 Million	-271,635 Reduced 8.84%	2,800,000 $189 Million
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $23.5 Million - $28.1 Million	460,000 Added 17.61%	3,071,635 $167 Million
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $23.6 Million - $30.2 Million	-463,365 Reduced 15.07%	2,611,635 $156 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $149 Million - $185 Million	3,075,000	3,075,000 $149 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.